Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

Pharmacokinetics (PK) profile of LNA-i-miR-221 in mice. (a) Plot of plasma concentrations at different time-points for LNA-i-miR-221 indicates a rapid plasmatic clearance from 1.5 to 6 hours after single dose injection (25 mg/kg), followed by a distribution phase, till to almost no detectability 6 hours after injection; (b) plasma LNA-i-miR-221 concentration (ng/ml) at each time point from 1.5 to 24 hours; (c–d) ISH for LNA-i-miR-221 in xenograft tumors of untreated (c) and treated animals (d) retrieved after 12 hours of single injection of LNA-i-miR-221 (25 mg/kg). **: BLQ ≤ LLQ (LLQ = 25 ng/ml).